OnKure Therapeutics (NASDAQ:OKUR) Posts Quarterly Earnings Results

OnKure Therapeutics (NASDAQ:OKUR) posted its quarterly earnings results on Monday. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51), Zacks reports.

OnKure Therapeutics Price Performance

OKUR stock opened at $4.96 on Tuesday. The firm has a market cap of $16.58 million, a price-to-earnings ratio of -0.41 and a beta of 0.28. OnKure Therapeutics has a 1-year low of $4.57 and a 1-year high of $20.00. The business’s 50 day simple moving average is $6.05.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Leerink Partners assumed coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price target on the stock. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.